Method for preparing a vaccine antigen, resulting vaccine antigen and uses

Patent metadata

Field	Value
Publication number	US-10144917-B2
Application number	US-201515507620-A
Country	US
Kind code	B2
Filing date	Aug 28, 2015
Priority date	Aug 29, 2014
Publication date	Dec 4, 2018
Grant date	Dec 4, 2018

Abstract

The present invention relates to a method for preparing a vaccine antigen, which includes a step of fragmenting a biological membrane associated with said vaccine antigen by treating said biological membrane with at least one calixarene of formula (II): wherein: X is a —(CH2)-CO2Y group and Y is an alkaline metal or one of the pharmaceutically acceptable salts thereof, wherein said resulting vaccine antigen also includes a fragment of the biological membrane associated with said antigen. The present invention also relates to a vaccine that can be produced by implementing the method, including a calixarene of formula (II) in carrier format, with a quantity of 0.1 to 1,000 μg in the total weight of the vaccine. The present invention further relates to the use of a calixarene as defined above for the preparation of a vaccine or a vaccine antigen, and to the vaccine for use as a drug in the treatment or prevention of an infectious disease.

First claim

The invention claimed is:

1. A process for preparing a vaccine antigen, comprising a step of fragmenting a biological membrane associated with said vaccine antigen by bringing said biological membrane into contact with at least one calixarene of formula (II):

in which:
X is a (CH 2 )—CO 2 Y group, and
Y is an alkali metal,

or a pharmaceutically acceptable salt thereof,
wherein said vaccine antigen obtained also comprises a fragment of the biological membrane, said fragment being associated with said antigen, and
wherein the vaccine antigen is a membrane protein of flu virus.

2. The process as claimed in claim 1 , wherein Y is sodium.

3. The process as claimed in claim 1 , wherein said biological membrane is derived from the flu virus.

4. The process as claimed in claim 1 , wherein said biological membrane is derived from an embryonated egg.

5. The process as claimed in claim 1 , wherein said vaccine antigen comprises a biological membrane of the flu virus.

6. The process as claimed in claim 1 , wherein said viral origin is chosen from the group comprising: the orthomyxoviridae virus family and the paramyxoviridae virus family.

7. The process as claimed in claim 6 , wherein said flu virus is chosen from influenza viruses A and influenza viruses B.

8. The process as claimed in claim 1 , also comprising a step of dialyzing said vaccine antigen.

9. A vaccine that can be produced by carrying out the process as defined in claim 1 , comprising a calixarene of formula (II) in excipient format in an amount of from 0.1 to 1000 μg in the total weight of the vaccine.

10. The vaccine as claimed in claim 9 , for application thereof as a medicament in the treatment or prevention of an infectious disease.

11. A process for preparing a vaccine antigen, consisting of a step of fragmenting a biological membrane associated with said vaccine antigen by bringing said biological membrane into contact with at least one calixarene of formula (II):

in which:
X is a (CH 2 )—CO 2 Y group, and
Y is an alkali metal,

or a pharmaceutically acceptable salt thereof,
wherein said vaccine antigen obtained also comprises a fragment of the biological membrane, said fragment being associated with said antigen, and
wherein the vaccine antigen is a membrane protein of flu virus.

Assignees

• Calixar
• Univ Claude Bernard Lyon
• Hospices Civils Lyon
• Inst Nat Sante Rech Med
• Univ Claud Bernard Lyon 1

Inventors

• Rosa-Calatrava Manuel
• Traversier Aurélien
• Desuzinges-Mandon Élodie
• Dejean Emmanuel

Classifications

• A61P31/14

  for RNA viruses · CPC title

• A61P31/20

  for DNA viruses · CPC title

• A61P31/12

  Antivirals · CPC title

• A61P31/16

  for influenza or rhinoviruses · CPC title

• A61P37/04

  Immunostimulants · CPC title